kabutan

SANTEN PHARMACEUTICAL CO.,LTD., July-September (2Q) Net Income Decreases by 8%

Thu Nov 7, 2024 3:00 pm JST Earnings

4536 SANTEN PHARMACEUTICAL CO.,LTD. 【IFRS】

Earnings Report

SANTEN PHARMACEUTICAL CO.,LTD. <4536> [TSE-P] announced its financial results (based on IFRS) in the afternoon session on November 7th (15:00). The consolidated net income for the cumulative second quarter of the fiscal year ending March 2025 (April to September) was 18.7 billion yen, a 2.6% decrease compared to the same period last year. The progress rate against the 33.5 billion yen full-year plan was 56.0%, below the five-year average of 82.2%.

Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated net income for the October to March period (second half) is expected to expand by 86.5% from the same period last year, reaching 13.7 billion yen.

In the most recent three-month period, from July to September (2Q), the consolidated net income decreased to 8.13 billion yen, a 8.2% decrease compared to the same period last year. The operating profit margin decreased from 16.8% in the same period last year to 15.0%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Sep, 2022 128,915 -19,021 -19,103 -22,041 -56.1 Nov 8, 2022 IFRS
Apr - Sep, 2023 145,806 25,099 24,075 19,280 52.1 80.6 Nov 7, 2023 IFRS
Apr - Sep, 2024 146,404 23,873 23,839 18,772 52.9 53.0 Nov 7, 2024 IFRS
YoY +0.4% -4.9% -1.0% -2.6% +1.6%

First Half Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2024 Guidance 17 May 9, 2024 IFRS
Apr - Sep, 2024 Results 146,404 23,873 23,839 18,772 52.9 17 Nov 7, 2024 IFRS
Revision Rate

Guidance Update

Full Year Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2025 Prev 302,000 44,500 45,000 34 Aug 6, 2024 IFRS
Mar, 2025 New 302,000 44,500 45,000 32,500 95.2 34 Nov 7, 2024 IFRS
Revision Rate 0.0% 0.0% 0.0%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2023 156,159 13,442 5,799 7,362 20.1 17 May 9, 2024 IFRS
Oct - Mar, 2024 Guidance 155,596 20,627 21,161 13,728 40.2 17 Nov 7, 2024 IFRS
YoY -0.4% +53.5% +264.9% +86.5% +100.5%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2023 279,037 -3,090 -5,799 -14,948 -38.6 32 May 11, 2023 IFRS
Mar, 2024 301,965 38,541 29,874 26,642 72.6 33 May 9, 2024 IFRS
Mar, 2025 Guidance 302,000 44,500 45,000 32,500 95.2 34 Nov 7, 2024 IFRS
YoY +0.0% +15.5% +50.6% +22.0% +31.2%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jul - Sep, 2023 73,417 12,349 11,207 8,866 23.9 16.8 Nov 7, 2023 IFRS
Oct - Dec, 2023 77,027 11,058 9,484 7,333 19.9 14.4 Feb 8, 2024 IFRS
Jan - Mar, 2024 79,132 2,384 -3,685 29 0.1 3.0 May 9, 2024 IFRS
Apr - Jun, 2024 74,771 13,155 13,450 10,633 29.6 17.6 Aug 6, 2024 IFRS
Jul - Sep, 2024 71,633 10,718 10,389 8,139 22.9 15.0 Nov 7, 2024 IFRS
YoY -2.4% -13.2% -7.3% -8.2% -4.2%

Related Articles